The new DxC 500i Analyzer Offers
Flexibility and Scalability with
Broad Chemistry and Immunoassay Assay Menu
BREA,
Calif., March 10, 2025 /PRNewswire/ -- Beckman
Coulter Diagnostics, a clinical diagnostics leader, today announced
that the new DxC 500i Clinical Analyzer, an integrated
clinical chemistry and immunoassay analyzer, received 510(k)
clearance from the U.S. Food and Drug Administration. The DxC 500i
combines advanced technology with an intuitive user interface,
ensuring that laboratories of all sizes can meet the growing
demands of modern healthcare. With throughput of up to 800 clinical
chemistry tests per hour and 100 immunoassay tests per hour, this
analyzer delivers precise and reliable results critical for timely
clinical decision-making.
Healthcare systems around the world and specifically in
the United States are
strategically adopting networked laboratory operational models for
better efficiency and patient access. Approximately 45% of clinical
laboratories in the United States
— a total of more than 11,000 labs — are associated with an
Integrated Delivery Network (IDN).i IDNs are
organizations that provide a coordinated range of healthcare
services, including diagnostic testing allowing for better resource
management, standardized practices, and enhanced quality of
care.
"Innovations like the DxC 500i Clinical Analyzer enable Beckman
Coulter to address the needs of networked laboratories with
specific solutions for satellite or independent laboratories, as
well as core laboratories," said Kathleen
Orland, Chief Portfolio Officer for Beckman Coulter
Diagnostics. "Beyond ensuring appropriate throughput levels for a
networked lab, Beckman Coulter's common reagents and consumables
across its scalable clinical chemistry and immunoassay portfolio
enables common reference ranges, offering IDNs strategic benefits
in patient care and inventory management."
The DxC 500i Clinical Analyzer features FlexMode operations,
prioritizing immunoassay and chemistry testing according to each
sample's urgency. The new dynamic sample handler manages repeats
and re-runs without operator intervention and pulls in a new sample
rack as soon as the previous rack is offloaded, optimizing rapid
throughput in a compact footprint. Of equal importance, the DxC
500i Analyzer's intuitive interface supports even the newest users
through proactive task indicators with step-by-step instructions,
simplifying staff onboarding and training.
The DxC 500i Clinical Analyzer has been available in countries
accepting CE mark since July
2024.
Prior to the DxC 500i Clinical Analyzer introduction, Beckman
Coulter unveiled the DxC 500 AU Chemistry Analyzer, an automated
clinical chemistry analyzer with onboard guided workflows, more
than 120 assays, and standardized reagents for use across
healthcare networks. The DxC 500i analyzer incorporates the DxC 500
AU technology within its clinical chemistry capabilities, including
its Six Sigma performance.
Not all products are available in all countries. Product
availability and regulatory status depends on country registration
per applicable regulations.
Follow and connect with Beckman Coulter Diagnostics
via LinkedIn, X, and Facebook.
About Beckman Coulter Diagnostics
A global leader in advanced diagnostics, Beckman Coulter has
challenged convention to elevate the diagnostic laboratory's role
in improving patient health for more than 90 years. Our mission is
to Relentlessly Reimagine Healthcare, One Diagnosis at a
Time — and we do this by applying the power of science,
technology and the passion and creativity of our teams. Our
diagnostic solutions are used in complex clinical testing, and are
found in hospitals, reference laboratories and physician office
settings around the globe. We exist to deliver smarter, faster
diagnostic solutions that move the needle forward from what's now
to what's next. We seek to accelerate care with an extensive
clinical menu, scalable lab automation technologies, insightful
clinical informatics, and to optimize lab performance services.
Headquartered in Brea, Calif.,
with more than 11,000 global team members, Beckman Coulter
Diagnostics is proud to be part of Danaher (NYSE: DHR). Danaher is
a global science and technology leader. Together we combine our
capabilities to accelerate the real-life impact of tomorrow's
science and technology to improve human health.
© 2025 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. The Danaher trademark is a
proprietary mark of Danaher Corporation. All other trademarks are
the property of their respective owners. 2025-14088
i Beckman Coulter Diagnostics internal data on
file
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-announces-fda-clearance-of-dxc-500i-clinical-analyzer-an-integrated-clinical-chemistry-and-immunoassay-system-302396960.html
SOURCE Beckman Coulter Diagnostics
